Bastion Therapeutics’ Post

The Power of Relationship in Digital Therapeutics: Debunking the Myth Discover how embedded digital therapeutics foster effective relationships, challenging the misconception of their absence. #DigitalTherapeutics #RelationshipMatters #DisembodiedPresence #SocialPsychology #LiteratureConnection #MoviesAndEmotions #HealthcareTechnology #VirtualRelationships #TherapeuticEffects #DigitalWellbeing

New partnership announcement coming out of CincyTech portfolio company Enable Injections, Inc.! Enable Injections and Serina Therapeutics, Inc. are teaming up to revolutionize Parkinson's Disease treatment. 🧠💉 Their recent agreement aims to develop SER-252 in combination with enFuse, offering advanced solutions for those battling Parkinson's Disease. 🔍 SER-252, coupled with enFuse technology, promises groundbreaking advancements in Parkinson's treatment. With enhanced delivery methods, this collaboration could significantly improve patients' quality of life. Read more about this game-changing partnership here: https://lnkd.in/e4KYSJdZ #ParkinsonsDisease #MedicalInnovation #HealthcareAdvancements

[BLOG POST] Dive Deeper into the Future of Therapeutics! Get ready for the next part of our ground-breaking blog series - 'The Future is Non-Viral,' where we delve even further into the exciting realm of therapeutic advancements. In this sequel, we continue to explore the insights shared by Ken LeClair, Chair of RoslinCT’s Scientific Advisory Board, uncovering the transformative potential of non-viral vector alternatives. Discover how cutting-edge cellular reprogramming techniques are revolutionizing the field and learn about the latest advancements that are reshaping tomorrow's therapies. Read the blog post: https://lnkd.in/ehQxp_an #TherapeuticDelivery #SABPerspectives #Roslinsights

This is a very flexible platform for screening and optimisation of small molecules directly against whole organism models..

🌍On #RareDiseaseDay, we stand with those facing rare diseases. At Ysios Capital we're proud to support pioneering #biotech companies developing treatments for #orphan and #rare diseases. Our investments target the high #unmet medical #needs, aiming to improve patient lives.🔬 🔄 The journey to bring #groundbreaking treatments from the #lab to the #patients is challenging but crucial. By #funding companies with the potential to make a real difference, we're not just investing in their success; we're investing in progress, and the future of #healthcare. 🌟 🎯 Backing the breakthroughs of tomorrow. SpliceBio Adcendo Minoryx Therapeutics Vivet Therapeutics AM-Pharma Synendos Therapeutics AG NorthSea Therapeutics Aura Biosciences KALA BIO #YsiosImpact #rarediseaseday2024 #vc #biotech #innovation #HealthInnovation

🚀 Exciting new advancements in CAR-T therapies for blood cancer treatment are underway! However, bottlenecks in infrastructure are posing challenges for treatment. Here are the key takeaways: 🏥 Leerink Partners warns of hospital investments needed for CAR-T growth, highlighting strained healthcare infrastructure. 👩⚕️ Referral challenges from community doctors to treatment centers has potential to hinder patient access. 📈 Existing treatment centers who adopted CAR-T therapies early on will need to expand their capacity by 125% of current growth projections to meet current patient needs. 🤝 Gilead's Kite explores novel approach, collaborating with oncology groups to strategically build CAR-T facilities. 💡 Comprehensive collaboration is needed to address hurdles and unlock CAR-T therapies' full potential. #CART #HealthcareInnovation #Biotech #CellTherapy #Innovation https://lnkd.in/eA_mpdCS

Curious about the groundbreaking advancements in microbiome-based therapeutics? Explore the insights shared by our Chief Scientific Officer, Christopher Weidenmaier, PhD, and Chief Technology Officer, Johannes B. Woehrstein, PhD, as they discuss the challenges and considerations in manufacturing LBPs 🧪 The journey to harnessing the power of the human microbiome is both exhilarating and complex. Discover the remarkable efficacy of complex live biotherapeutic products (LBPs) in modulating the microbiome, evidenced by the recent approvals of Rebyota and VOWST. Read the full article on EPR to uncover the future of microbiome-based treatments: https://bit.ly/4bhMqAw #LBPs #MicrobiomeTherapeutics #BiotechInnovation #ScienceAndTechnology #EPR

Are you interested in studying platelet-derived EVs to exploit their roles in immune response, inflammation, and wound healing for novel diagnostics and therapeutics? Then, our brand-new product platelet EVs developed in collaboration with Laitinen Saara and Finnish Red Cross - Suomen Punainen Risti is just for you! Our optimized isolation protocol ensures their scalable manufacturing, reproducibility, as well as a consistent lipoprotein content reduction in comparison with standard methods. Depending on your use case, platelet EVs are available in lyophilized or frozen form. If you are interested in knowing more about the product: https://lnkd.in/dwXiK-kA #extracellularvesicles #exosomes #plateletEVs

What is it like to live with thyroid eye disease (TED)? Viridian Therapeutics, Inc. is studying multiple candidates in clinical studies for TED, and recently met with a group of individuals living with TED to gain a deeper understanding about their lived experiences. The image below shares some of what the company learned about people's varied and individualized journeys with the disease. Learn more at https://lnkd.in/eZTGdQ9m #biotech #TED

𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐆𝐋𝐏-𝐈 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🔥 The landscape of GLP-1 therapies is rapidly expanding, with potential impacts now reaching into cardiovascular risk, sleep apnoea, and liver disease. Among startups, Viking Therapeutics, Inc., and Altimmune, Inc. have garnered attention for their promising GLP-1 candidates focused on weight loss. Viking's VK2735 showed significant weight loss of up to 13% in a Phase 2 trial over 13 weeks, without plateauing, suggesting potential for further reduction with longer treatment. 👉 Novo's recent FDA approval for Wegovy, extending its use to cardiovascular risk reduction, illustrates the path forward for broadening therapeutic applications. Full credit to Arjun Murphy and MavenBio.Io - great work. #obesity #biotech #biopharma